Skip to main content

Kara Wegermann

Assistant Professor of Medicine
Medicine, Gastroenterology

Overview


My research focuses on genetic predictors of progression in non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). I have investigated predictors of clinical progression in non-alcoholic fatty liver disease using the Duke NAFLD clinical database and biorepository. I find the genetic and modifiable risk factors for liver disease fascinating, particularly because of the potential for clinical intervention before cirrhosis or HCC are established.

Current Appointments & Affiliations


Assistant Professor of Medicine · 2024 - Present Medicine, Gastroenterology, Medicine

Recent Publications


Predictors of Respiratory Failure Development in a Multicenter Cohort of Inpatients With Cirrhosis.

Journal Article Am J Gastroenterol · April 1, 2024 INTRODUCTION: Hospitalized patients with cirrhosis can develop respiratory failure (RF), which is associated with a poor prognosis, but predisposing factors are unclear. METHODS: We prospectively enrolled a multicenter North American cirrhosis inpatient co ... Full text Link to item Cite

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease

Journal Article Metabolism and Target Organ Damage · January 1, 2024 Metabolic dysfunction-associated steatotic liver disease (MASLD) has an increasing prevalence, morbidity, and mortality both within the United States and globally. Here, we review newer evidence demonstrating racial and ethnic disparities that exist in the ... Full text Cite

Fatty Liver Disease: Enter the Metabolic Era.

Journal Article Curr HIV/AIDS Rep · December 2023 PURPOSE OF REVIEW: The goal of this review is to summarize the recent literature linking HIV to metabolic dysfunction-associated steatotic liver disease (MASLD). This is a pressing issue due to the scale of the MASLD epidemic and the urgent need for preven ... Full text Link to item Cite
View All Publications

Recent Grants


Genomic Imprinting in the Development of NAFLD

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2028

Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis

ResearchCo Investigator · Awarded by University of Texas - Southwestern · 2023 - 2027

The Southeastern Liver Health Cohort Study

ResearchCo Investigator · Awarded by North Carolina State University · 2023 - 2027

View All Grants

Education, Training & Certifications


Harvard Medical School · 2014 M.D.